EBITDA: Income before interest, taxes, depreciation and amortization.
Rein Therapeutics Inc. (RNTX) had EBITDA of $-6.07M for the most recently reported fiscal quarter, ending 2024-09-30.
| Income Statement Financials | |
-- |
|
$-5.85M |
|
-- |
|
-- |
|
$6.07M |
|
$-6.07M |
|
$0.22M |
|
$-5.85M |
|
$-5.85M |
|
$-5.85M |
|
$-5.85M |
|
$-5.85M |
|
$-5.85M |
|
$-6.07M |
|
|
EBITDA |
$-6.07M |
21.66M |
|
21.66M |
|
$-0.27 |
|
$-0.27 |
|
| Balance Sheet Financials | |
$18.68M |
|
$0.00M |
|
$85.53M |
|
$104.22M |
|
$5.66M |
|
-- |
|
$48.33M |
|
$53.99M |
|
$50.23M |
|
$-35.30M |
|
$50.23M |
|
21.67M |
|
| Cash Flow Statement Financials | |
$-17.48M |
|
-- |
|
$17.82M |
|
$17.34M |
|
$17.68M |
|
$0.34M |
|
$0.98M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.30 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-17.48M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-11.64% |
|
16.56% |
|
-5.61% |
|
-11.64% |
|
$2.32 |
|
$-0.81 |
|
$-0.81 |
|